Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSSM 001

Next Previous
Drug Profile

OSSM 001

Alternative Names: CHYMALIS; Chymelis; Mesenchymal stem cell therapy - Ossium Health; Ossium vBM-MSC; OSSM-001

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ossium Health
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Crohn's disease
  • No development reported Radiation injuries

Most Recent Events

  • 28 May 2025 No recent reports of development identified for research development in Radiation-injuries in USA (Parenteral, Injection)
  • 23 Dec 2022 Ossium Health withdraws a phase I trial prior to enrolment in Graft versus host disease (IV, Infusion) due to the reason that OSSM 001 will not be used in this program moving forward (NCT05443464)
  • 21 Dec 2022 Ossium Health withdraws a phase I trial prior to enrolment in Crohn's disease (In adults, In the elderly) (Parenteral, Injection) due to the reason that OSSM 001 will not be used in this clinical program (NCT05407766)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top